UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000037430
Receipt number R000042554
Scientific Title Effect of Frailty on Elderly Patients Receiving Intensive Care: Prospective Multicenter Observational Study
Date of disclosure of the study information 2019/07/21
Last modified on 2023/04/12 14:14:20

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Prognosis and QOL Study on Elderly Patients Receiving Intensive Care

Acronym

LIFE (Looking into Intensive care setting on Frailty of Elderly) study

Scientific Title

Effect of Frailty on Elderly Patients Receiving Intensive Care: Prospective Multicenter Observational Study

Scientific Title:Acronym

LIFE (Looking into Intensive care setting on Frailty of Elderly) study

Region

Japan


Condition

Condition

Patients recieving intesive care.
Patients aged over 65.

Classification by specialty

Emergency medicine Intensive care medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The present study is designed to clarify the prognosis and quality of life after emergency intensive care for elderly patients in Japan. Effect of frailty on prognosis, quality of life, and activity of daily living are examined.

Basic objectives2

Others

Basic objectives -Others

Effect of frailty on elderly patients receiving intensive care.

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Six month survival according to each frailty.

Key secondary outcomes

1. Twenty-eight day survival according to each frailty.
2. Quality of life six months after admission and the change according to each frailty.
3. Activity of daily living six months after admission and the change according to each frailty.
4. Location (other facility/home) after intensive care according to each frailty.
5. Total medical expenses according to each frailty.


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

65 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Consecutive patients who met the following criteria in 3 month period.
1. Patients who visited the emergency rooms of the participating facilities. to the intensive care unit of the participating facilities though the emergency rooms.
2. Patients who admitted directory to the intensive care unit though the emergency rooms.
3. Patients who are aged 65 and over 65.

Key exclusion criteria

Patients with missing Clinical Frailty Scale before the transport.

Target sample size

1000


Research contact person

Name of lead principal investigator

1st name Hiromichi
Middle name
Last name Naito

Organization

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

Division name

Department of Emergency, Critical Care, and Disaster Medicine

Zip code

700-8558

Address

2-5-1 Shikatacho, Kitaku, Okayama

TEL

086-235-7427

Email

naito05084@gmail.com


Public contact

Name of contact person

1st name Mototaka
Middle name
Last name Inaba

Organization

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

Division name

Department of Emergency, Critical Care, and Disaster Medicine

Zip code

700-8558

Address

2-5-1 Shikatacho, Kitaku, Okayama

TEL

086-235-7427

Homepage URL


Email

pau546oq@s.okayama-u.ac.jp


Sponsor or person

Institute

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,
Department of Emergency, Critical Care, and Disaster Medicine

Institute

Department

Personal name



Funding Source

Organization

Ministry of education

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences and Okayama University Hospital, Ethics Committee

Address

2-5-1 Shikatacho, Kitaku, Okayama

Tel

086-235-6938

Email

mae6605@adm.okayama-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 07 Month 21 Day


Related information

URL releasing protocol

https://okayama-u-qq.sakura.ne.jp/research

Publication of results

Published


Result

URL related to results and publications

https://www.nature.com/articles/s41598-023-32519-2

Number of participants that the trial has enrolled

650

Results

955 cases were screened for eligibility, 650 was included in the study. The median age was 79 (IQR 72-85) years. Overall mortality at 6-month was 21% ranging from CFS1: 6.2% to CFS>7: 42.9%. Six-month mortality increased with higher CFS. CFS was an independent prognostic factor (one-point increase in CFS, adjusted RR: 1.19 [1.09 - 1.30]). Quality of life (EQ5D index and VAS) worsened with higher CFS. Proportion of patients who could directly discharge home decreased with higher CFS.

Results date posted

2022 Year 02 Month 07 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

The median age was 79 (IQR 72-85) years, 58.5% were male. 84.3% of the patients lived home without assistance before admission, and 6.8% were living at home with service. The remaining 6.5% of the patients were admitted from nursing homes. The median Charlson Comorbidity Index (CCI) was 5 (4-6) and the median CFS was 3 (3-5). Frailty (CFS>4) was observed in 26.6% of patients. The median APACHE2 score was 22 (16-29).

Participant flow

Patients were enrolled from 19 participating centers in Japan during four consecutive months for each facility between November 2019 and April 2020. 955 cases were screened for eligibility, after excluding the patients, 650 were included in the study. Quality of life using the EQ5D were available in 534 patients.

Adverse events

nothing in particular

Outcome measures

Primary endpoint: 6-month mortality by CFS

Secondary endpoints:
EQ5D index by CFS.
Rate of discharges to patient housing by CFS
Total medical costs by CFS

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2019 Year 02 Month 01 Day

Date of IRB

2019 Year 03 Month 08 Day

Anticipated trial start date

2019 Year 11 Month 01 Day

Last follow-up date

2020 Year 08 Month 31 Day

Date of closure to data entry

2020 Year 11 Month 30 Day

Date trial data considered complete

2020 Year 12 Month 31 Day

Date analysis concluded

2021 Year 03 Month 31 Day


Other

Other related information

Observations will be conducted for the following data and responses to the questionnaires.
1. Participating facility information
2. Patient characteristics
3. Treatment
4. Severity
5. Outcome
6. Questionnaires including frailty scale and quality of life at admission
7. Questionnaires including quality of life six month after admission


Management information

Registered date

2019 Year 07 Month 20 Day

Last modified on

2023 Year 04 Month 12 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042554


Research Plan
Registered date File name
2021/07/28 研究計画書v5.0_200930.docx

Research case data specifications
Registered date File name
2021/07/28 症例・除外基準191009.pdf

Research case data
Registered date File name